Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Barcelona, Joan XXIII 27-32, CP 08028 Barcelona, Spain.
Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Barcelona, Joan XXIII 27-32, CP 08028 Barcelona, Spain.
Int J Pharm. 2018 May 30;543(1-2):190-200. doi: 10.1016/j.ijpharm.2018.03.052. Epub 2018 Mar 28.
During the development of parenteral dosage forms, different physicochemical studies are required to ensure stable, effective and safe formulations. The osmolality of this kind of dosage forms should bear a close similarity to the body fluids to prevent local irritation, pain or even more significant side effects like endothelial damage. The osmotic studies performed in Polyethylene glycol 400 (PEG 400), Polyethylene glycol 4000 (PEG 4000), Poloxamer 407 (P407), Sodium Hyaluronate (SH), Chondroitin Sulphate Sodium (CS), Cremophor RH 40 (CRE40) and Polyvinyl alcohol (PVA) aqueous solutions, showed that the theoretical determination of the osmolality based on their molecular weight as the only determinant factor did not agree with the values obtained by the measurement of colligative properties such as the freezing point depression. The data obtained from this study and its analysis, provided predictive equations that can be used as tools in the primary development to estimate formulation's osmolality at different concentrations; and its evolution over a period at the hypothetical worst-case scenario of storage temperature.
在开发肠外剂型时,需要进行不同的物理化学研究,以确保制剂稳定、有效和安全。这类剂型的渗透压应与体液密切相似,以防止局部刺激、疼痛,甚至更严重的副作用,如内皮损伤。在聚乙二醇 400(PEG 400)、聚乙二醇 4000(PEG 4000)、泊洛沙姆 407(P407)、透明质酸钠(SH)、硫酸软骨素钠(CS)、吐温 40(CRE40)和聚乙烯醇(PVA)水溶液中的渗透压研究表明,基于分子量作为唯一决定因素的渗透压理论测定值与冰点降低等依数性质测量值不一致。本研究获得的数据及其分析提供了预测方程,可以用作初步开发的工具,以在不同浓度下估计制剂的渗透压;以及在假设的最坏储存温度情况下,在一段时间内的演变。